Omeros announces publication detailing the mechanism of action of pde7 in nicotine addiction

Seattle--(business wire)--omeros corporation (nasdaq: omer), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced publication of the article “selective inhibition of phosphodiesterase 7 enzymes reduces motivation fo
OMER Ratings Summary
OMER Quant Ranking